Wednesday, 4 December 2019

Male Breast Cancer Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Market Scenario:
Although breast cancer is common in women, even men suffer from the same. Men also have breast tissues and cancer starts when these tissues start to grow out of control. The breast ducts and glands present in men are not functional, but cancer in these areas can spread when cancer cells enter the blood or lymph system and are carried in the whole body. Men who have suffered from cancer before and undergone radiation therapy are at a high risk of suffering from male breast cancer.
The rising geriatric population and an increasingly obese population resulting in high levels of estrogen in males are expected to drive the growth of the market during the forecast period. According to an article published by the National Cancer Institute in April 2018, most of the men who suffer from breast cancer are 60 to 70 years old. Additionally, the rising healthcare expenditure is likely to boost the market growth. On the other hand, lack of knowledge of the disease and high cost of treatment may hinder the growth of the market during the forecast period.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
The global male breast cancer market is expected to grow slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Key players
Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.
Segmentation
The global male breast cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833. Europe is expected to hold the second largest position in the global male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Browse Complete 100  Pages Premium Research Report Enabled with 90 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/male-breast-cancer-market-6505
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Worldwide Pulmonary Atresia Diagnostics and Treatment Market 2019 Outlook, top 10 Industry players comprehensive analysis and Forecast to 2023

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.
The Global Pulmonary Atresia Diagnostics and Treatment Market is expected to register a significant growth during the forecast period (2018–2023).
The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 
Key Players
Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.
Segmentation
The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.
On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.
On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.
On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.
In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.
Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.
The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pulmonary-atresia-diagnostics-treatment-market-6487
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Fibrocystic Breasts Diagnostics and Treatment Market - Granular Market Report and Review, 2019

More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Browse Complete 100 Pages Premium Research Report Enabled with 75 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/fibrocystic-breasts-diagnostics-treatment-market-6448  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Duodenal Cancer Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine. The global duodenal cancer market is expected to grow slowly over the forecast period. It is estimated that the global duodenal cancer market is expected to register a CAGR ~ 3.2% during the forecast period of 2018–2023.
Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.\
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the global duodenal cancer market.
Segmentation
The global duodenal cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.
The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.
The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Summary
Geographically, the Americas is anticipated to dominate the global duodenal cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% of people diagnosed with duodenal cancer survive it for five years. Europe is expected to hold the second largest position in the global duodenal cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for the healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora, Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Distraction Osteogenesis Devices Market to Observe Significant Growth by 2019

Global Distraction Osteogenesis Devices Market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.
Browse Complete 90 Pages Premium Research Report Enabled with 94 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/distraction-osteogenesis-devices-market-6392  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Cardiopulmonary Disease Diagnostics and Treatment Market to Observe Significant Growth by 2019

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the growth of the market.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
In the cardiopulmonary disease diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.
 The European market is expected to hold the second largest market share. The market growth in this region can be attributed to rising frequency of cardiovascular disorders, increasing number of surgeries and increasing demand for advanced treatment procedures are boosting the European market.
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.
The market in the Middle East and Africa is expected to account for the smallest share of the global cardiopulmonary disease diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cardiopulmonary-disease-diagnostics-treatment-market-6390
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Verrucous Carcinoma Market 2019 - Opportunity, Driving Trends and deep study 2023

Market Scenario:
Verrucous carcinoma (VC) is a rare type of squamous cell carcinoma and is categorized under head and neck cancer.  It is mainly caused due to the chewing of tobacco or snuffing it orally. It is also called as snuff dipper's cancer. Verrucous carcinoma most commonly occurs at oral sites but is also observed in head and neck genital locations. It is mainly observed in males than in females and is found in the age group of 50 to 80 years.
The key factor responsible for influencing this market is the increasing prevalence of oral cancer. It may also be caused due to lifestyle factors such as smoking tobacco or marijuana, alcohol consumption, and others. Other key factors such as a change to sedentary lifestyle, growing consumption of alcohol, increasing tobacco users of dip, snuff, increase in smoking, rising family history of cancer prevalence, and increasing prevalence of sexually transmitted diseases by human papillomavirus are contributing towards the growth of the market. According to the World Health Organization in 2015, globally 1.1 billion people smoked tobacco. This is expected to provide favorable backgrounds for market growth during the forecast period.
However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments, and side effects associated with treatments are expected to restrict the market growth during the forecast period.
Key players
Some of the key players in the global verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others.
Segmentation
The global verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.
On the basis of region, the global verrucous carcinoma market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Market Summary
It is estimated that North America dominated the global verrucous carcinoma market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society in August 2018 granted USD 15,866,878 for head and neck cancer research projects. This influences the market growth in this region
Asia-Pacific was projected to be the fastest growing region for the global verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of oral cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of oral cavity and pharynx cancer in 2017 in Japan. Such a high incidence of oral cancer favors the market growth in this region.
According to the World Health Organization’s Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of tobacco smoking among adults that is 28% of adults in Europe are engaged in tobacco smoking. Such a high prevalence of smoking in this region facilitates the market growth. Europe stood second largest in the verrucous carcinoma market owing to the increasing use of tobacco.
The Middle East and Africa holds the least share in the global verrucous carcinoma market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/verrucous-carcinoma-market-6367
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)